Clik here to view.
Dr. Reddy’s Laboratories Announces the Launch of Pemetrexed for Injection...
HYDERABAD, India & PRINCETON, N.J. Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today...
View ArticleClik here to view.
武田和Seagen呈报的ADCETRIS®联合用药数据显示，晚期霍奇金淋巴瘤患者的总生存(OS)改善有统计学意义
马萨诸塞州剑桥和日本大阪和华盛顿州博瑟尔 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE:4502)和Seagen Inc., (NASDAQ:SGEN)今天宣布，ADCETRIS® (brentuximab...
View ArticleClik here to view.
Takeda Presents Latest Research from Oncology Portfolio and Pipeline at ASCO...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will present data at two upcoming scientific congresses this spring:...
View ArticleClik here to view.
武田薬品とシーゲンが進行期ホジキンリンパ腫の患者で全生存期間（OS）の統計的に有意な改善を示すアドセトリス併用療法のデータを発表へ
米マサチューセッツ州ケンブリッジ & 大阪 & 米ワシントン州ボセル （ビジネスワイヤ） —...
View ArticleClik here to view.
武田在ASCO和EHA上展示肿瘤学产品组合和研发产品线的最新研究成果
马萨诸塞州坎布里奇和日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited,...
View ArticleClik here to view.
武田薬品がASCOおよびEHAでオンコロジー分野のポートフォリオとパイプラインに関する最新研究の成果を発表
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） —...
View ArticleClik here to view.
CANbridge Pharmaceuticals to Present at the Jefferies Global Healthcare...
BEIJING & CAMBRIDGE, Mass. CANbridge Pharmaceuticals Inc. (HKEX:1228), a China-based global biopharmaceutical company committed to the research, development and commercialization of...
View ArticleClik here to view.
BOEHRINGER INGELHEIM ENTERS GLOBAL LICENSING AGREEMENT TO DEVELOP AND...
INGELHEIM, Germany & SINGAPORE Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim...
View ArticleClik here to view.
Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor...
ST. HELIER, Jersey & SHANGHAI, China & SAN FRANCISCO & CAMBRIDGE, Mass. Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forms...
View ArticleClik here to view.
Patritumab Deruxtecan Continues to Show Promising Clinical Activity in...
TOKYO & MUNICH & BASKING RIDGE, N.J. New data from Daiichi Sankyo’s (TSE: 4568) patritumab deruxtecan (HER3-DXd) showed clinically meaningful and durable responses in two early-stage trials...
View ArticleClik here to view.
MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American...
SAN DIEGO & TOKYO MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global...
View ArticleClik here to view.
ENHERTU® Reduced the Risk of Disease Progression or Death by 50% vs....
TOKYO & MUNICH & BASKING RIDGE, N.J. Detailed positive results from the pivotal DESTINY-Breast04 phase 3 trial showed that ENHERTU® (trastuzumab deruxtecan) demonstrated superior and...
View ArticleClik here to view.
Latest Data of InnoCare’s Orelabrutinib for the Treatment of SLE Presented at...
BEIJING InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that Professor Zhanguo Li, the leading PI, has presented latest data of BTK inhibitor orelabrutinib for the...
View ArticleClik here to view.
Genuv Teams With Nanocarry Therapeutics to Develop Novel anti-PD-1 mAb...
SEOUL, South Korea & NESS ZIONA, Israel Genuv Inc., a clinical-stage biotechnology company focused on innovative drug discovery for central nervous system disorders and advanced antibody...
View ArticleClik here to view.
Latest Data of InnoCare’s Robust Oncology Pipelines Presented at the 2022...
BEIJING Latest data of InnoCare’s robust oncology pipeline were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Poster Presentation 1: Phase I results of...
View ArticleClik here to view.
Genexine reports encouraging top-line results of the Phase 1b/2 clinical...
SEOUL, South Korea Genexine (KOSDAQ: 095700) a publicly traded, clinical stage biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet...
View ArticleClik here to view.
EpimAb Biotherapeutics Announces U.S. FDA Clearance of IND Application for...
SHANGHAI & SUZHOU, China EpimAb Biotherapeutics, a clinical-stage biotechnology company specializing in bispecific antibody development, today announced that the U.S. Food and Drug...
View ArticleClik here to view.
Clik here to view.
New Data on Ropeginterferon Alfa-2b to Be Featured at EHA2022
TAIPEI PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology...
View ArticleClik here to view.
Exscientia将出席高盛第43届全球医疗保健年会
英格兰牛津 (美国商业资讯)–Exscientia (Nasdaq: EXAI)今天宣布，Exscientia创始人兼首席执行官Andrew Hopkins博士和首席运营官Dave Hallett将于太平洋时间2022年6月14日星期二上午9:20（英国夏令时下午5:20）参加高盛第43届全球医疗保健年会的炉边谈话。...
View Article